Case report: safety and efficacy of omalizumab in a 13-year-old patient with chronic spontaneous urticaria and type 1 diabetes

HIGHLIGHTS

• who: Paolo Del Barba from the University Hospital SchleswigHolstein, Germany have published the research work: Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes, in the Journal: (JOURNAL)

SUMMARY

Frontiers in Immunology | www.frontiersin.org April 2022 | Volume 13 | Article 853561 Omalizumab in CSU and T1DM Antihistamines are the first-line treatment for CSU, and if the standard dose is not effective, the dosage can be increased fourfold. Omalizumab was approved by the the authors Food and Drug Administration and the . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.